financetom
Business
financetom
/
Business
/
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Jan 14, 2025 3:02 PM

NEW YORK, Jan 14 (Reuters) - Pfizer ( PFE ) on Tuesday

appealed a federal judge's refusal to award the drugmaker $75.2

million from a more than decade-old insider trading settlement

involving billionaire Steven A. Cohen's former hedge fund, SAC

Capital Management.

The money was left over from SAC's $602 million settlement

in March 2013 with the U.S. Securities and Exchange Commission

over trades in drugmakers Wyeth and Elan by Mathew Martoma, who

worked at an SAC unit and was later convicted.

Pfizer ( PFE ) said it deserved the $75.2 million because a

neurologist who tipped Martoma about a 2008 Alzheimer's drug

trial owed a fiduciary duty to Wyeth, which Pfizer ( PFE ) bought in

2009, because he had been a consultant there.

U.S. District Judge Victor Marrero in Manhattan, however,

ruled in November that Wyeth was not a victim of Martoma's

trading, and thus Pfizer ( PFE ) was not entitled to funds left over

after Wyeth and Elan investors who lost money were compensated.

Pfizer ( PFE ) appealed Marrero's decision to the 2nd U.S. Circuit

Court of Appeals in Manhattan. The appeals process often takes

several months or longer.

Cohen was not criminally charged. He changed SAC Capital's

name to Point72 Asset Management in 2014, and is now worth $21.3

billion according to Forbes magazine.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verona Pharma Q4 Loss Widens
Verona Pharma Q4 Loss Widens
Feb 27, 2025
06:18 AM EST, 02/27/2025 (MT Newswires) -- Verona Pharma ( VRNA ) reported a Q4 loss Thursday of $0.05 per diluted share, compared with a loss of $0.02 a year earlier. Analysts polled by FactSet expected a loss of $0.19. Revenue for the quarter ended Dec. 31 was $36.7 million. The company did not report any revenue in the year-ago...
Ferrari's Largest Shareholder Exor Pares Down Stake
Ferrari's Largest Shareholder Exor Pares Down Stake
Feb 27, 2025
06:18 AM EST, 02/27/2025 (MT Newswires) -- Ferrari (RACE) stakeholder Exor said Thursday that it has sold 7 million of its shares in the Italian carmaker, or about 4% of the total outstanding shares of the company, to institutional investors for total proceeds of 3 billion euros ($3.14 billion). . Ferrari said Thursday that it committed to buying 666,666 of...
Commerzbank on Overnight News
Commerzbank on Overnight News
Feb 27, 2025
06:21 AM EST, 02/27/2025 (MT Newswires) -- Commerzbank in its European Sunrise note of Thursday highlighted: Markets: United States Treasuries rally into New York close, retreat in Asia. Asian equities are mixed, e-minis supported. EUR below $1.047, Brent steady around $72.8/barrel. Fed: Atlanta Federal Reserve President Raphael Bostic says policy is restrictive and needs to stay restrictive. He sees inflation...
Standard Chartered lays out detailed net zero transition plan
Standard Chartered lays out detailed net zero transition plan
Feb 27, 2025
(Reuters) - Standard Chartered ( SCBFF ) on Thursday disclosed a detailed plan outlining its integration of climate considerations into its business operations, aiming for net zero targets across its financing activities by 2050 and its operations by 2025. The plan comes a few days after the bank pledged to continue its net-zero strategy and reduce emissions associated with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved